Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilana Schlam

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
NPJ Breast Cancer|May 21, 2021
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is nowIlana Schlam, Sandra M Swain
The Oncologist|May 22, 2022
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain MetastasesIlana Schlam, Margaret E Gatti-Mays
Oncotargets and Therapy|May 5, 2022
Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast CancerIlana Schlam, Raquel Nunes, Filipa Lynce
Current Oncology Reports|February 23, 2024
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?Ilana Schlam, Joshua Dower, Filipa Lynce
Breast (Edinburgh, Scotland)|January 20, 2023
How I treat HER2-low advanced breast cancerIlana Schlam, Sara M Tolaney, Paolo Tarantino
Expert Opinion on Drug Safety|November 23, 2023
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancerIlana Schlam, Antonio Giordano, Sara M Tolaney
Expert Opinion on Biological Therapy|October 6, 2023
Managing adverse events of sacituzumab govitecanIlana Schlam, Paolo Tarantino, Sara M Tolaney
Expert Review of Anticancer Therapy|January 24, 2023
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancerIlana Schlam, Sara M Tolaney, Paolo Tarantino
Cancers|August 26, 2022
Overcoming Resistance to HER2-Directed Therapies in Breast CancerIlana Schlam, Paolo Tarantino, Sara M Tolaney
Critical Reviews in Oncology/Hematology|August 10, 2023
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2Ilana Schlam, Ruth Moges, Stefania Morganti, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
NPJ Breast Cancer|May 21, 2021
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is nowIlana Schlam, Sandra M Swain
The Oncologist|May 22, 2022
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain MetastasesIlana Schlam, Margaret E Gatti-Mays
Oncotargets and Therapy|May 5, 2022
Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast CancerIlana Schlam, Raquel Nunes, Filipa Lynce
Current Oncology Reports|February 23, 2024
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?Ilana Schlam, Joshua Dower, Filipa Lynce
Breast (Edinburgh, Scotland)|January 20, 2023
How I treat HER2-low advanced breast cancerIlana Schlam, Sara M Tolaney, Paolo Tarantino
Expert Opinion on Drug Safety|November 23, 2023
Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancerIlana Schlam, Antonio Giordano, Sara M Tolaney
Expert Opinion on Biological Therapy|October 6, 2023
Managing adverse events of sacituzumab govitecanIlana Schlam, Paolo Tarantino, Sara M Tolaney
Expert Review of Anticancer Therapy|January 24, 2023
The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancerIlana Schlam, Sara M Tolaney, Paolo Tarantino
Cancers|August 26, 2022
Overcoming Resistance to HER2-Directed Therapies in Breast CancerIlana Schlam, Paolo Tarantino, Sara M Tolaney
Critical Reviews in Oncology/Hematology|August 10, 2023
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2Ilana Schlam, Ruth Moges, Stefania Morganti, et al.
Pageof 4